Beta-2 agonists are a class of medicines commonly used to treat many respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD).Beta-2 agonists are usually referred to as bronchodilators because they make breathing easier by dilating the bronchi and relaxing the muscles in the airways. They mimic the functions of catecholamines such as dopamine, epinephrine, and norepinephrine, in producing various autonomic responses within the body. Beta-2 agonists are classified either as Short-acting Beta-2 agonists (SABAs) which provide quick relief of symptoms, Long-acting Beta-2 agonists (LABAs), and ultra-LABAs which are used to prevent as well as control symptoms. This article outlines the current evidence-based therapeutic applications of Beta-2 agonists. It also covers the mechanism of action, adverse effects, and therapeutic applications of Beta-2 agonists. This article aims to give healthcare providers the knowledge that can assist them in making an informed healthcare decision regarding a Beta-2 agonist so that they can ensure optimal patient care.
Ganga, N. (2022). The use of short-acting and long-acting Beta-2-agonists in the treatment of respiratory diseases. Trends in Pharmaceutical Sciences, (), -. doi: 10.30476/tips.2022.94061.1132
MLA
Nelisa Paidamwoyo Ganga. "The use of short-acting and long-acting Beta-2-agonists in the treatment of respiratory diseases", Trends in Pharmaceutical Sciences, , , 2022, -. doi: 10.30476/tips.2022.94061.1132
HARVARD
Ganga, N. (2022). 'The use of short-acting and long-acting Beta-2-agonists in the treatment of respiratory diseases', Trends in Pharmaceutical Sciences, (), pp. -. doi: 10.30476/tips.2022.94061.1132
VANCOUVER
Ganga, N. The use of short-acting and long-acting Beta-2-agonists in the treatment of respiratory diseases. Trends in Pharmaceutical Sciences, 2022; (): -. doi: 10.30476/tips.2022.94061.1132
)